Literature DB >> 15361222

Malignant perivascular epithelioid cell tumor (PEComa) arising in the broad ligament.

D Fink1, D E Marsden, L Edwards, C Camaris, N F Hacker.   

Abstract

Malignant perivascular epithelioid cell tumor (PEComa) is an extremely rare mesenchymal neoplasm mostly composed of HMB-45-positive epithelioid cells with clear-to-eosinophilic cytoplasm, a propensity for perivascular distribution and a coexpression of smooth muscle markers. The uterus seems to be one of the most prevalent sites of involvement, although only 14 cases of uterine PEComa have been described. We report the case of a 51-year-old woman with a PEComa arising in the broad ligament. She was treated with total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic radiation, and remains without evidence of disease 15 months after diagnosis. This is, to the best of our knowledge, the first report of a malignant PEComa arising in the broad ligament. To correctly diagnose PEComa, an extensive immunohistochemical panel is essential. As PEComas can behave in an aggressive manner, careful follow-up is warranted.

Entities:  

Mesh:

Year:  2004        PMID: 15361222     DOI: 10.1111/j.1048-891X.2004.014549.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  15 in total

Review 1.  Perivascular epithelioid tumours (PEComas) of the gynaecological tract.

Authors:  Niamh Conlon; Robert A Soslow; Rajmohan Murali
Journal:  J Clin Pathol       Date:  2015-03-06       Impact factor: 3.411

2.  Coincidence between malignant perivascular epithelioid cell tumor arising in the gastric serosa and lung adenocarcinoma.

Authors:  Sohsuke Yamada; Atsunori Nabeshima; Hirotsugu Noguchi; Aya Nawata; Hisae Nishii; Xin Guo; Ke-Yong Wang; Masanori Hisaoka; Toshiyuki Nakayama
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  Perivascular epithelioid cell neoplasms (PEComas): four malignant cases expanding the histopathological spectrum and a description of a unique finding.

Authors:  Ilan Weinreb; David Howarth; Eleanor Latta; Danny Ghazarian; Runjan Chetty
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

Review 4.  Primary perivascular epithelioid cell neoplasm (PEComa) of bone: report of two cases and review of the literature.

Authors:  Nicholas M Desy; Mitchell Bernstein; Ayoub Nahal; Mohamed Aziz; Samuel Kenan; Robert E Turcotte; Leonard B Kahn
Journal:  Skeletal Radiol       Date:  2012-07-03       Impact factor: 2.199

5.  Endometrial polyp-like perivascular epithelioid cell neoplasm associated with TFE3 translocation: report of one case.

Authors:  Yanting Hu; Lixia Wang; Hongqi Shi; Bin Hu
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

6.  Malignant clear-cell myomelanocytic tumor of broad ligament--a case report.

Authors:  Hyun-Jung Kim; Sung-Jig Lim; Hoon Choi; Kyeongmee Park
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

7.  Perivascular epithelioid cell tumor of the rib.

Authors:  Ikuko Torii; Nobuyuki Kondo; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Ayuko Sato; Fumihiro Tanaka; Takashi Nishigami; Seiki Hasegawa; Tohru Tsujimura
Journal:  Virchows Arch       Date:  2008-04-24       Impact factor: 4.064

8.  A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report.

Authors:  Claire Ross; Sunita Sharma; Onsy Louca; Michelle Scurr; Andrew Hayes; Ian Judson
Journal:  J Med Case Rep       Date:  2011-08-16

9.  "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.

Authors:  Jonathan S Bleeker; J Fernando Quevedo; Andrew L Folpe
Journal:  Sarcoma       Date:  2012-04-26

10.  Perivascular epithelioid cell tumor (PEComa) of abdominal cavity from falciform ligament: a case report.

Authors:  Cheol Woong Choi; Tae Oh Kim; Kyung Yeob Kim; Sun Mi Lee; Gwang Ha Kim; Dae Hwan Kang; Geun Am Song; Suk Kim; Dae Hwan Kim
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.